Advanced

IgG glycan hydrolysis by EndoS diminishes the pro-inflammatory properties of immune complexes from patients with SLE - a possible new treatment?

Lood, Christian LU ; Allhorn, Maria LU ; Lood, Rolf LU ; Gullstrand, Birgitta LU ; Olin, Anders LU ; Rönnblom, Lars; Truedsson, Lennart LU ; Collin, Mattias LU and Bengtsson, Anders LU (2012) In Arthritis and Rheumatism 71.
Abstract
OBJECTIVE.: Systemic lupus erythematosus (SLE) is an autoimmune disease with chronic or episodic inflammation in several organ systems, related to the presence of circulating and tissue-deposited immune complexes (ICs) which stimulate leukocytes through FcγRs with subsequent inflammation. Treatment with EndoS, an IgG glycan hydrolyzing bacterial enzyme from Streptococcus pyogenes, has shown beneficial effects in several experimental animal models of chronic inflammatory disease. In the present study we asked if EndoS could affect pro-inflammatory properties of ICs and have the potential to be developed as a therapy in SLE.



METHODS.: ICs, purified from SLE patients or RNA-containing ICs formed in vitro, were treated with... (More)
OBJECTIVE.: Systemic lupus erythematosus (SLE) is an autoimmune disease with chronic or episodic inflammation in several organ systems, related to the presence of circulating and tissue-deposited immune complexes (ICs) which stimulate leukocytes through FcγRs with subsequent inflammation. Treatment with EndoS, an IgG glycan hydrolyzing bacterial enzyme from Streptococcus pyogenes, has shown beneficial effects in several experimental animal models of chronic inflammatory disease. In the present study we asked if EndoS could affect pro-inflammatory properties of ICs and have the potential to be developed as a therapy in SLE.



METHODS.: ICs, purified from SLE patients or RNA-containing ICs formed in vitro, were treated with EndoS and used in several assays reflecting different important parts of SLE pathogenesis such as phagocytosis by polymorphonuclear neutrophils (PMNs) and plasmacytoid dendritic cells (pDCs), complement activation and IFNα production by pDCs.



RESULTS.: Our results demonstrate that EndoS treatment could abolish all pro-inflammatory properties of ICs investigated. This includes FcγR-mediated phagocytosis by pDCs (p<0.0001) and subsequent production of IFNα (p<0.0001), IC-induced classical complement pathway activation (p<0.0001), chemotaxis and oxidative burst activity of PMNs (p=0.002). We could also demonstrate direct effects on the molecular structure of ICs after EndoS treatment with decreased size and glycosylation patterns.



CONCLUSIONS.: Prominent effects of EndoS treatment were seen in several pathogenetically important IC-mediated events and our data suggest that EndoS have the potential to be developed as a novel therapy in SLE. © 2012 American College of Rheumatology. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Arthritis and Rheumatism
volume
71
publisher
John Wiley & Sons
external identifiers
  • wos:000302323600003
  • pmid:22392566
ISSN
1529-0131
DOI
10.1136/annrheumdis-2011-201230.2
language
English
LU publication?
yes
id
b4d7c9cf-66ac-4c6b-b11d-d7a9da4915df (old id 2432217)
date added to LUP
2012-04-03 08:55:51
date last changed
2016-04-16 05:52:23
@article{b4d7c9cf-66ac-4c6b-b11d-d7a9da4915df,
  abstract     = {OBJECTIVE.: Systemic lupus erythematosus (SLE) is an autoimmune disease with chronic or episodic inflammation in several organ systems, related to the presence of circulating and tissue-deposited immune complexes (ICs) which stimulate leukocytes through FcγRs with subsequent inflammation. Treatment with EndoS, an IgG glycan hydrolyzing bacterial enzyme from Streptococcus pyogenes, has shown beneficial effects in several experimental animal models of chronic inflammatory disease. In the present study we asked if EndoS could affect pro-inflammatory properties of ICs and have the potential to be developed as a therapy in SLE. <br/><br>
<br/><br>
METHODS.: ICs, purified from SLE patients or RNA-containing ICs formed in vitro, were treated with EndoS and used in several assays reflecting different important parts of SLE pathogenesis such as phagocytosis by polymorphonuclear neutrophils (PMNs) and plasmacytoid dendritic cells (pDCs), complement activation and IFNα production by pDCs. <br/><br>
<br/><br>
RESULTS.: Our results demonstrate that EndoS treatment could abolish all pro-inflammatory properties of ICs investigated. This includes FcγR-mediated phagocytosis by pDCs (p&lt;0.0001) and subsequent production of IFNα (p&lt;0.0001), IC-induced classical complement pathway activation (p&lt;0.0001), chemotaxis and oxidative burst activity of PMNs (p=0.002). We could also demonstrate direct effects on the molecular structure of ICs after EndoS treatment with decreased size and glycosylation patterns. <br/><br>
<br/><br>
CONCLUSIONS.: Prominent effects of EndoS treatment were seen in several pathogenetically important IC-mediated events and our data suggest that EndoS have the potential to be developed as a novel therapy in SLE. © 2012 American College of Rheumatology.},
  author       = {Lood, Christian and Allhorn, Maria and Lood, Rolf and Gullstrand, Birgitta and Olin, Anders and Rönnblom, Lars and Truedsson, Lennart and Collin, Mattias and Bengtsson, Anders},
  issn         = {1529-0131},
  language     = {eng},
  publisher    = {John Wiley & Sons},
  series       = {Arthritis and Rheumatism},
  title        = {IgG glycan hydrolysis by EndoS diminishes the pro-inflammatory properties of immune complexes from patients with SLE - a possible new treatment?},
  url          = {http://dx.doi.org/10.1136/annrheumdis-2011-201230.2},
  volume       = {71},
  year         = {2012},
}